Table 2.
Follow-up time and medication adherence among patients with baseline uncontrolled A1C, BP, or LDL cholesterol, by intervention vs. control condition
| Patients with uncontrolled A1C |
Patients with uncontrolled SBP (mm Hg) |
Patients with uncontrolled LDL cholesterol (mg/dL) |
|||||||
|---|---|---|---|---|---|---|---|---|---|
| Control | Intervention | P value | Control | Intervention | P value | Control | Intervention | P value | |
| Follow-up ≥60 days | 533 | 569 | 403 | 388 | 315 | 348 | |||
| Yes | 530 (99.4) | 563 (98.9) | 0.373 | 395 (98.0) | 383 (98.7) | 0.445 | 310 (98.4) | 344 (98.9) | 0.583 |
| Follow-up ≥180 days | 533 | 569 | 403 | 388 | n = 315 | n = 348 | |||
| Yes | 501 (94.0) | 529 (93.0) | 0.593 | 365 (90.6) | 347 (89.4) | 0.646 | 294 (93.3) | 327 (94.0) | 0.668 |
| Drug coverage and follow-up ≥60 days | 533 | 569 | 403 | 388 | 315 | 348 | |||
| Yes | 458 (85.9) | 481 (84.5) | 0.885 | 317 (78.7) | 296 (76.3) | 0.445 | 270 (85.7) | 299 (85.9) | 0.572 |
| Drug coverage and follow-up ≥180 days | 533 | 569 | 403 | 388 | 315 | 348 | |||
| Yes | 436 (81.8) | 456 (80.1) | 0.792 | 295 (73.2) | 275 (70.9) | 0.590 | 260 (82.5) | 289 (83.0) | 0.551 |
| Primary adherence by the index date | 458 | 481 | 317 | 296 | 270 | 299 | |||
| Yes | 348 (76.0) | 365 (75.9) | 0.932 | 241 (76.0) | 234 (79.1) | 0.389 | 189 (70.0) | 182 (60.9) | 0.023 |
| Primary adherence within 60 days of new prescription | 458 | 481 | 317 | 296 | 270 | 299 | |||
| Yes | 401 (87.6) | 413 (85.9) | 0.540 | 263 (83.0) | 254 (85.8) | 0.354 | 221 (81.9) | 238 (79.6) | 0.474 |
| Nonpersistence (<2 fills) at 180 days | 436 | 456 | 295 | 275 | 260 | 289 | |||
| Yes | 165 (37.8) | 151 (33.1) | 0.141 | 117 (39.7) | 99 (36.0) | 0.301 | 134 (51.5) | 150 (51.9) | 0.725 |
| MPR | 316 | 341 | 202 | 214 | 164 | 174 | |||
| Mean ± SD | 0.793 ± 0.24 | 0.802 ± 0.22 | 0.903 | 0.922 ± 0.129 | 0.900 ± 0.159 | 0.126 | 0.846 ± 0.178 | 0.851 ± 0.184 | 0.839 |
| Median (minimum–maximum) | 0.912 (0.151–1.000) | 0.881 (0.215–1.000) | 1.000 (0.278–1.000) | 0.995 (0.188–1.000) | 0.909 (0.292–1.000) | 0.930 (0.175–1.000) | |||
| Change from baseline | 463 | 506 | 368 | 363 | 251 | 288 | |||
| Mean ± SD | −1.33 ± 1.87% (−13 mmol/mol) | −1.16 ± 1.80% (−12 mmol/mol) | 0.149 | −16.4 ± 18.75 | −18.1 ± 20.56 | 0.255 | −33.0 ± 38.36 | −30.4 ± 39.02 | 0.438 |
| Median (minimum to maximum) | −1.20% (−8.8 to 6.0%) | −1.00% (−11.0 to 4.7%) | −16.0 (−103 to 42) | −17.0 (−82 to 57) | −30.0 (−162 to 74) | −28.5 (−175 to 110) | |||
| Decrease from baseline* | 463 | 506 | 368 | 363 | 251 | 288 | |||
| Yes | 348 (75.2) | 373 (73.7) | 0.639 | 279 (75.8) | 285 (78.5) | 0.380 | 189 (75.3) | 218 (75.7) | 0.901 |
| A1C change from baseline among late fillers† | 92 | 103 | 68 | 61 | 66 | 98 | |||
| Mean ± SD | −0.90 ± 1.85% (−9 mmol/mol) | −1.08 ± 1.78% (−11 mmol/mol) | 0.476 | −15.6 ± 16.74 | −19.6 ± 21.60 | 0.248 | −22.3 ± 37.78 | −29.2 ± 35.53 | 0.227 |
| Median (minimum to maximum) | −0.95% (−7.5 to 4.0%) (−9 mmol/mol) | −0.90% (−6.8 to 3.6%) (−9 mmol/mol) | −14.5 (−54 to 30) | −17.5 (−68 to 25) | −17.0 (−112 to 74) | −29.0 (−108 to 110) | |||
Data are n (%), unless otherwise specified.
*For A1C decrease form baseline of ≥0.2%.
†Late filler is patient with drug coverage who filled a new prescription after the index date.